Cagrilintide is a long-acting amylin analogue investigated in rodent models and human trials for its influence on appetite and body weight. This overview examines what the primary literature actually reports about its receptor biology, molecular design, and translational evidence, framed strictly for research use.

Amylin biology and where cagrilintide fits

Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Reviews of amylin physiology describe it as a physiological signal of meal-ending satiation that also limits the rate of gastric emptying and suppresses postprandial glucagon secretion³. These actions are mediated primarily through direct activation of neurons in the caudal hindbrain rather than through peripheral tissues³.

Native amylin is not a practical research or therapeutic molecule on its own: it aggregates readily and has a short circulating half-life. The first analogue to reach clinical use was pramlintide, a synthetic amylin analogue used as replacement therapy in insulin-treated diabetes, where it slows accelerated gastric emptying, restores meal-related glucagon suppression, and modestly reduces body weight⁷⁸. Pramlintide requires mealtime dosing, which motivated the search for longer-acting molecules.

Cagrilintide (also written AM833) is a lipidated, long-acting amylin analogue engineered for once-weekly administration in research settings. A narrative review characterises it as an amylin analogue developed to achieve sustained effects on food intake, and increasingly studied in combination with the GLP-1 receptor agonist semaglutide⁵. It sits within a broader class of dual amylin–calcitonin receptor agonists now being examined across obesity and metabolic research programmes².

How cagrilintide is proposed to influence appetite

Amylin binds to a heterodimeric receptor formed by the calcitonin receptor (CTR) combined with one of three receptor-activity-modifying proteins (RAMP1, RAMP2, or RAMP3). Different CTR–RAMP pairings define the amylin receptor subtypes commonly labelled AMY1R, AMY2R, and AMY3R². This modular architecture is central to how amylin analogues are studied, because it determines receptor selectivity and where in the brain the signal is transduced.

Mechanistic work localises the primary site of action to the hindbrain. In rodent studies, amylin and its analogues activate neurons in the area postrema and the dorsal vagal complex (DVC), with downstream signalling relayed to the lateral parabrachial nucleus (LPBN)². Neuronal activation is typically tracked using the immediate-early gene product c-Fos. The proposed sequence is that circulating cagrilintide engages CTR–RAMP receptors on hindbrain neurons, triggering satiation signalling that reduces food intake, alongside slowed gastric emptying that prolongs the sensation of fullness after a meal³⁴.

Beyond simple energy intake, review literature notes that amylin can act as a sensitiser to the catabolic actions of leptin, which is one reason amylin-based molecules attract interest as components of combination approaches³. It is important to state the evidence boundary plainly: the detailed circuit-level mechanism described here derives largely from rodent experiments and receptor pharmacology, not from direct human neuronal measurements.

Molecular design, albumin binding, and half-life

The design feature that distinguishes cagrilintide from native amylin and from pramlintide is lipidation. A fatty-acid side chain is attached to the peptide backbone, which promotes reversible, non-covalent binding to serum albumin. Albumin binding acts as a circulating reservoir that slows renal clearance and extends the functional half-life, the pharmacological basis for once-weekly dosing schedules used in trials⁵. The same lipidation strategy has been applied to other long-acting peptides, so it is a well-characterised chemical approach rather than a novel or unproven one.

From a research-handling perspective, this design matters for reasons beyond pharmacokinetics. Analogue stability, aggregation behaviour, and reconstitution consistency all influence whether in vitro and in vivo results are reproducible between laboratories. Amylin's native tendency to form amyloid fibrils is precisely the property that makes careful analogue engineering and consistent formulation important for reliable experimental work⁴.

The table summarises how these molecules relate; the regulatory column is the key honest caveat. Pramlintide is an approved mealtime adjunct in diabetes⁸, whereas cagrilintide remains an investigational compound.

Preclinical evidence: receptor dependence

A 2025 rodent study provides some of the clearest mechanistic evidence for how cagrilintide lowers body weight. Working in RAMP1 and RAMP3 double-knockout mice fed a high-fat diet, investigators compared cagrilintide with salmon calcitonin over a three-week treatment period². In wild-type animals, cagrilintide produced body-weight loss and reduced food intake during the first days of treatment, and it activated c-Fos signalling in the DVC and LPBN. In the RAMP1/3 knockout animals, cagrilintide's potency on weight loss was blunted and area-postrema c-Fos activation was reduced by roughly 57% relative to wild-type controls².

The authors interpret these results as demonstrating that cagrilintide's body-weight effect depends on amylin receptors 1 and 3². Two points deserve emphasis for anyone reading this as research context. First, the finding is a receptor-dependence result in genetically modified mice, not a human observation. Second, the same study noted that removing RAMP1 and RAMP3 improved salmon calcitonin's efficacy while impairing cagrilintide's, underscoring that closely related dual amylin–calcitonin agonists do not share identical mechanisms. Preclinical receptor-selectivity data of this kind are exactly what support rational design but do not, by themselves, establish translational outcomes.

Human trial evidence in weight management

The most cited human dataset for cagrilintide monotherapy is a phase 2, multicentre, randomised, double-blind, placebo- and active-controlled dose-finding trial reported in 2021¹. It enrolled 706 adults without diabetes who had obesity, or overweight with a weight-related comorbidity, across ten countries. Participants received once-weekly subcutaneous cagrilintide at doses from 0.3 to 4.5 mg, once-daily liraglutide 3.0 mg as an active comparator, or placebo, over a 26-week treatment period.

According to the trial-product estimand, mean percentage weight reductions from baseline were greater across all cagrilintide doses (approximately 6.0% at 0.3 mg up to 10.8% at 4.5 mg) than with placebo (about 3.0%)¹. At the top dose, cagrilintide 4.5 mg produced a greater reduction than liraglutide 3.0 mg (10.8% versus 9.0%; estimated treatment difference 1.8%). The most frequent adverse events were gastrointestinal (nausea, constipation, diarrhoea) and administration-site reactions; permanent treatment discontinuation occurred in about 10% of participants, mostly due to adverse events¹. The authors framed the data as supporting further development of novel-mechanism molecules for weight management rather than as a definitive efficacy verdict.

The combination direction

Much of the subsequent human research pairs cagrilintide with semaglutide, the fixed combination referred to as CagriSema. A 2025 phase 3a randomised, placebo-controlled trial (REDEFINE 2) tested once-weekly cagrilintide–semaglutide at 2.4 mg each in 1,206 adults with overweight or obesity and type 2 diabetes over 68 weeks⁶. The estimated mean change in body weight was −13.7% with the combination versus −3.4% with placebo, a difference of about 10.4 percentage points, and a larger proportion of participants reached weight reductions of at least 5%, 10%, 15%, and 20%⁶. Gastrointestinal adverse events were reported by roughly 72% of the combination group versus 34% of placebo, though most were described as transient and mild-to-moderate⁶.

A pharmacological review of the combination rationale explains why the two molecules are studied together: amylin analogues and GLP-1 receptor agonists act through related but distinct pathways, and their effects on appetite appear additive rather than redundant⁵. This is a recurring theme in obesity pharmacology reviews, which increasingly frame multi-hormone combinations as a logical response to the heterogeneous physiology of body-weight regulation¹⁰.

Cardiometabolic context and combination research

Cagrilintide is studied within a fast-moving landscape of incretin- and amylin-based molecules. Reviews of this field group it alongside GLP-1 receptor agonists such as semaglutide, the dual GLP-1/GIP agonist tirzepatide, and the triple agonist retatrutide, noting that second-generation agents have been associated with substantially greater weight reductions than earlier options in controlled trials¹¹. Within that framing, the cagrilintide–semaglutide combination is positioned as one of several approaches expected to push weight-loss magnitudes into ranges previously associated mainly with surgery¹².

The metabolic rationale extends beyond the scale. Reviews emphasise that the gut–brain axis integrates multiple nutrient-stimulated hormones to regulate appetite and glucose handling, and that targeting several of these signals simultaneously is being explored to improve cardiometabolic variables in addition to body weight¹². In the REDEFINE 2 diabetes population, a markedly higher proportion of combination-treated participants reached a glycated haemoglobin level of 6.5% or below compared with placebo, illustrating the glycaemic dimension of amylin–incretin co-agonism⁶. General obesity-pharmacotherapy reviews caution, however, that regulatory frameworks and long-term outcome data have historically lagged behind the pace of molecular development¹⁰.

Open questions and research directions

Several questions remain genuinely open, and honest research writing should name them rather than paper over them.

Duration and generalisability

The monotherapy phase 2 dataset covered 26 weeks in adults without diabetes¹, and even the larger combination trial ran to 68 weeks in a specific diabetes population⁶. Longer follow-up across more diverse populations is needed before durability of any effect can be characterised. Obesity-drug reviews repeatedly stress that maintenance of weight change over multi-year horizons is a distinct and harder question than short-term response⁹.

Mechanistic resolution

The receptor-dependence data are compelling in rodents, but the transcriptomic analysis in the RAMP1/3 study found that neither cagrilintide nor salmon calcitonin significantly altered gene expression in the DVC or LPBN after three weeks, pointing instead to roles in synaptic function and receptor trafficking². How central and peripheral pathways combine, and how tolerance or receptor desensitisation might develop, are unresolved.

Formulation and reproducibility

Because lipidated amylin analogues depend on precise structure for albumin binding and on controlled conditions to avoid aggregation, consistent synthesis and validated handling are prerequisites for reproducible experiments⁴. Assay variability and stability testing over the extended half-life window are practical research challenges, not incidental details.

Combination and biomarker strategy

Finally, review literature frames the future of the field around rational combinations and personalisation, including predictive biomarkers of response and careful attention to immunogenicity and receptor selectivity¹⁰¹¹. These remain aspirations supported by early data rather than settled conclusions.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.